Erratum: Impacts of the glucuronidase genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on tamoxifen metabolism in breast cancer patients (PLoS ONE (2015) 10:7 (e0132269) DOI: 10.1371/journal.pone.0132269);Impacts of the glucuronidase genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on tamoxifen metabolism in breast cancer patients

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Romero Lorca, Alicia ^a   Novillo, Apolonia ^a   Gaibar, María ^a   Bandrés, Fernando ^b   Fernández Santander, Ana ^a  

^a UNIVERSIDAD EUROPEA DE MADRID   (Spain)

^b Breast Pathology Center   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXY TAMOXIFEN N BETA DEXTRO GLUCURONIDE; 4 HYDROXY TAMOXIFEN O BETA DEXTRO GLUCURONIDE; BETA GLUCURONIDASE; DRUG METABOLITE; ENDOXIFEN O BETA DEXTRO GLUCURONIDE; TAMOXIFEN; UNCLASSIFIED DRUG; BILIRUBIN GLUCURONOSIDE GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE; MINOR HISTOCOMPATIBILITY ANTIGEN; UDP-GLUCURONOSYLTRANSFERASE 2B15, HUMAN; UGT2B17 PROTEIN, HUMAN; UGT2B7 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BREAST CANCER; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DESCRIPTIVE RESEARCH; DRUG BLOOD LEVEL; ENZYME ACTIVITY; FEMALE; GENE; GENE DELETION; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOZYGOSITY; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TANDEM MASS SPECTROMETRY; UGT1A4 GENE; UGT2B15 GENE; UGT2B17 GENE; UGT2B7 GENE; ALLELE; BLOOD; BREAST TUMOR; DEMOGRAPHY; ENZYMOLOGY; GENETICS; MASS SPECTROMETRY; METABOLISM; METABOLOME; MIDDLE AGED;

ALLELES; BREAST NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEMOGRAPHY; FEMALE; GENE FREQUENCY; GENOTYPE; GLUCURONIDASE; GLUCURONOSYLTRANSFERASE; HUMANS; MASS SPECTROMETRY; METABOLOME; MIDDLE AGED; MINOR HISTOCOMPATIBILITY ANTIGENS; TAMOXIFEN;

EID: 84941360366     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0140921     Document Type: Erratum

References (44)

1. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor- positive tumors. J Natl Cancer Ins. 1996; 88: 1529-1542.
2. Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV, et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat. 2004; 85(2): 151-159. PMID: 15111773
3. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005; 97(1): 30-9. PMID: 15632378
4. Lim HS, Lee HJ, Lee KS, Lee ES, Jang IJ, Ro J. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol. 2007; 25(25): 3837-45. PMID: 17761971
5. Kiyotani K, Mushiroda T, Imamura CK, Hosono N, Tsunoda T, Kubo M, et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol. 2010; 28(8): 1287-93. doi: 10.1200/JCO.2009.25.7246 PMID: 20124171
6. Fernández-Santander A, Gaibar M, Novillo A, Romero-Lorca A, Rubio M, Chicharro LM et al. Relationship between genotypes Sult1a2 and Cyp2d6 and tamoxifen metabolism in breast cancer patients. PLoS One. 2013;29; 8(7): e70183. doi: 10.1371/journal.pone.0070183 PMID: 23922954
7. Lien EA, Solheim E, Lea OA, Lundgren S, Kvinnsland S, Ueland PM. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res. 1989; 49: 2175-2183. PMID: 2702659
8. Poon GK, Chui YC, McCague R, Llnning PE, Feng R, Rowlands MG, et al. Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients. Drug Metab Dispos. 1993; 21: 1119-1124. PMID: 7905393
9. Lien EA, Solheim E, Kvinnsland S, Ueland PM. Identification of 4- hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile. Cancer Res. 1988; 48: 2304-2308. PMID: 3349495
10. Nowell SA, Ahn J, Rae JM, Scheys JO, Trovato A, Sweeney C, et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat. 2005; 91: 249-258. PMID: 15952058
11. Sun D, Chen G, Dellinger RW, Duncan K, Fang JL, Lazarus P. Characterization of tamoxifen and 4- hydroxytamoxifen glucuronidation by human UGT1A4 variants. Breast Cancer Res. 2006; 8: R50. PMID: 16884532
12. Sun D, Sharma AK, Dellinger RW, Blevins-Primeau AS, Balliet RM, Chen G, et al. Glucuronidation of active tamoxifen metabolites by the human UDP-glucuronosyltransferases (UGTs). Drug Metab Dispos. 2007; 35: 2006-14. PMID: 17664247
13. Nishiyama T, Ogura K, Nakano H, Ohnuma T, Kaku T, Hiratsuka A, et al. Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases. Biochem Pharmacol. 2002; 63: 1817-1830. PMID: 12034366
14. Kaku T, Ogura K, Nishiyama T, Ohnuma T, Muro K, Hiratsuka A. Quaternary ammonium-linked glucuronidation of tamoxifen by human liver microsomes and UDP-glucuronosyltransferase 1A4. Biochem Pharmacol. 2004; 67: 2093-2102. PMID: 15135306
15. Green MD, Tephly TR. Glucuronidation of amine substrates by purified and expressed UDP-glucuronosyltransferase proteins. Drug Metab Dispos. 1998; 26: 860-867. PMID: 9733664
16. Breyer-Pfaff U, Mey U, Green MD, Tephly TR. Comparative N-glucuronidation kinetics of ketotifen and amitriptyline by expressed human UDP-glucuronosyltransferases and liver microsomes. Drug Metab Dispos. 2000; 28: 869-872. PMID: 10901693
17. Mürdter D, Doerge DR, Fang JL, Upadhyaya P, Lazarus P. Characterization of N-glucuronidation of the lung carcinogen 4- (methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) inhuman liver: importance of UDP-glucuronosyltransferase 1A4. Drug Metab Dispos. 2004; 32: 72-79. PMID: 14709623
18. Ehmer U, Vogel A, Schutte JK, Krone B, Manns MP, Strassburg CP. Variation of hepatic glucuronidation: Novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4. Hepatology. 2004; 39: 970-977. PMID: 15057901
19. Zhou J, Argikar UA, Remmel RP. Functional analysis of UGT1A4P24T and UGT1A4L48V variant enzymes. Pharmacogenomics. 2011; 12(12): 1671-1679. doi: 10.2217/pgs.11.105 PMID: 22047493
20. Wiener D, Doerge DR, Fang JL, Upadhyaya P, Lazarus P. Characterization of N-glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in human liver: importance of UDP-glucuronosyltransferase 1A4. Drug Metab Dispos. 2004; 32(1): 72-9. PMID: 14709623
21. Turgeon D, Carrier JS, Lévesque E, Beatty BG, Bélanger A, Hum DW. Isolation and characterization of the human UGT2B15 gene, localized within a cluster of UGT2B genes and pseudogenes on chromosome 4. J Mol Biol. 2000; 295: 489-504. PMID: 10623541
22. WilsonW3rd, Pardo-Manuel de Villena F, Lyn-Cook BD, Chatterjee PK, Bell TA, Detwiler DA, et al. Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15. Genomics. 2004;Oct; 84(4): 707-14. PMID: 15475248
23. He XL, Hesse LM, Hazarika S, Masse G, Harmatz JS, Greenblatt DJ, et al. Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion. Br J Clin Pharmacol. 2009;Nov; 68(5): 721-30. doi: 10.1111/j.1365- 2125.2009.03519.x PMID: 19916996
24. Schulze JJ1, Thörngren JO, Garle M, Ekström L, Rane A. Androgen sulfation in healthy UDP-glucuronosyl transferase 2B17 enzyme-deficient men. J Clin Endocrinol Metab. 2011;Nov; 96(11): 3440-7. doi: 10.1210/jc.2011-0521 PMID: 21849521
25. Chen F, Ritter JK, Wang MG, McBride OW, Lubet RA, Owens IS. Characterization of a cloned human dihydrotestosterone/androstanediol UDP-glucuronosyltransferase and its comparison to other steroid isoforms. Biochemistry. 1993; 32: 10648-57. PMID: 8399210
26. Green M, Oturo E, Tephly T. Stable expression of a human liver UDP-glucuronosyltransferase (UGT2B15) with activity toward steroid and xenobiotic substrates. Drug Metab Dispos. 1994; 22: 799-805. PMID: 7835232
27. Court MH, Hao Q, Krishnaswamy S, Bekaii-Saab T, Al-Rohaimi A, Von Moltke LL, et al. UDPglucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver. J Pharmacol Exp Ther. 2004; 310: 656-65. PMID: 15044558
28. Mürdter TE, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W, et al. Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma. Clin Pharmacol Ther. 2011; 89(5): 708-17. doi: 10.1038/clpt.2011.27 PMID: 21451508
29. Blevins-Primeau AS, Sun D, Chen G, Sharma AK, Gallagher CJ, Amin S, et al. Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009;1; 69(5): 1892-900. doi: 10.1158/0008-5472.CAN-08-3708 PMID: 19244109
30. Lazarus P1, Blevins-Primeau AS, Zheng Y, Sun D. Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen. Ann N Y Acad Sci. 2009; 1155: 99-111. doi: 10.1111/j. 1749-6632.2009.04114.x PMID: 19250197
31. Benoit-Biancamano MO, Adam JP, Bernard O, Court MH, Leblanc MH, Caron P, et al. A pharmacogenetics study of the human glucuronosyltransferase UGT1A4. Pharmacogenet Genomics. 2009; 19(12): 945-954. doi: 10.1097/FPC.0b013e3283331637 PMID: 19890225
32. Saeki M, Saito Y, Jinno H, Sai K, Hachisuka A, Kaniwa N, et al. Genetic variations and haplotypes of UGT1A4 in a Japanese population. Drug Metab Pharmacokinet. 2005; 20(2); 144-151. PMID: 15855727
33. Lampe JW, Bigler J, Bush AC, Potter JD. Prevalence of polymorphisms in the human UDP-glucuronosyltransferase 2B family: UGT2B4(D458E), UGT2B7(H268Y), and UGT2B15(D85Y). Cancer Epidemiol Biomarkers Prev. 2000; 9(3): 329-33. PMID: 10750673
34. Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst. 2012;21; 104(6): 452-60. doi: 10.1093/jnci/djs126 PMID: 22395643
35. Greer AK, Dates CR, Starlard-Davenport A, Edavana VK, Bratton SM, Dhakal IB, et al. A potential role for human UDP-glucuronosyltransferase 1A4 promoter single nucleotide polymorphisms in the pharmacogenomics of tamoxifen and its derivatives. Drug Metab Dispos. 2014;Sep; 42(9): 1392-400. doi: 10.1124/dmd.114.058016 PMID: 24917585
36. Schulze JJ, Lorentzon M, Ohlsson C, Lundmark J, Roh HK, Rane A, et al. Genetic aspects of epitestosterone formation and androgen disposition: influence of polymorphisms in CYP17 and UGT2B enzymes. Pharmacogenet Genomics. 2008;Jun; 18(6): 477-85. doi: 10.1097/FPC.0b013e3282fad38a PMID: 18496127
37. Chen G, Giambrone NE Jr, Dluzen DF, Muscat JE, Berg A, Gallagher CJ, et al. Glucuronidation genotypes and nicotine metabolic phenotypes: importance of functional UGT2B10 and UGT2B17 polymorphisms. Cancer Res. 2010;1; 70(19): 7543-52. doi: 10.1158/0008-5472.CAN-09-4582 PMID: 20876810
38. Nadeau G1, Bellemare J, Audet-Walsh é, Flageole C, Huang SP, Bao BY, et al. Deletions of the androgen- metabolizing UGT2B genes have an effect on circulating steroid levels and biochemical recurrence after radical prostatectomy in localized prostate cancer. J Clin Endocrinol Metab. 2011;Sep; 96(9): E1550-7. doi: 10.1210/jc.2011-1049 PMID: 21733997
39. Chung JY, Cho JY, Yu KS, Kim JR, Jung HR, Lim KS, et al. Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers. Clin Pharmacol Ther. 2005; 77(6): 486-94. PMID: 15961980
40. Strahm E, Sjöberg U, Garle M, Rane A, Ekström L. Implication of Human UGT2B7, 2B15, and 2B17 in 19-Norandrosterone Metabolism. Front Endocrinol (Lausanne). 2013;26; 4: 75. doi: 10.3389/fendo. 2013.00075
41. Wiener D, Fang JL, Dossett N, Lazarus P. Correlation between UDP-glucuronosyltransferase genotypes and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone glucuronidation phenotype in human liver microsomes. Cancer Res. 2004; 64(3): 1190-6. PMID: 14871856
42. Damodaran SE, Pradhan SC, Umamaheswaran G, Kadambari D, Reddy KS. Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy. Cancer Chemother Pharmacol. 2012; 70(1): 75-81. doi: 10.1007/s00280-012-1891-1 PMID: 22623212
43. Gjerde J, Hauglid M, Breilid H, Lundgren S, Varhaug JE, Kisanga ER, et al. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol. 2008; 19: 56-61. PMID: 17947222
44. Gjerde J, Geisler J, Lundgren S, Ekse D, Varhaug JE, Mellgren G, et al. Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC Cancer 2010; 21: 10-313.